Name | Number of supported studies | Average coverage | |
---|---|---|---|
plasma cell | 27 studies | 70% ± 21% | |
plasmacytoid dendritic cell | 21 studies | 65% ± 12% | |
plasmablast | 10 studies | 65% ± 20% | |
IgG plasma cell | 9 studies | 59% ± 17% | |
IgA plasma cell | 8 studies | 70% ± 16% | |
B cell | 5 studies | 38% ± 30% | |
ciliated cell | 4 studies | 26% ± 8% | |
IgM plasma cell | 4 studies | 50% ± 13% |
Insufficient scRNA-seq data for expression of DERL3 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
pancreas | 100% | 2631.73 | 328 / 328 | 86% | 4.04 | 153 / 178 |
lung | 89% | 730.10 | 516 / 578 | 90% | 6.94 | 1036 / 1155 |
thymus | 97% | 1575.74 | 632 / 653 | 76% | 3.63 | 458 / 605 |
stomach | 76% | 1456.37 | 272 / 359 | 79% | 4.15 | 225 / 286 |
intestine | 56% | 1880.15 | 541 / 966 | 80% | 3.79 | 422 / 527 |
ovary | 48% | 174.30 | 87 / 180 | 84% | 4.50 | 362 / 430 |
breast | 43% | 375.82 | 196 / 459 | 80% | 3.51 | 899 / 1118 |
uterus | 35% | 284.12 | 59 / 170 | 74% | 3.40 | 340 / 459 |
bladder | 38% | 268.10 | 8 / 21 | 66% | 2.82 | 331 / 504 |
liver | 65% | 444.60 | 148 / 226 | 38% | 1.19 | 155 / 406 |
spleen | 100% | 4331.30 | 241 / 241 | 0% | 0 | 0 / 0 |
kidney | 64% | 468.40 | 57 / 89 | 33% | 1.08 | 299 / 901 |
tonsil | 0% | 0 | 0 / 0 | 93% | 9.19 | 42 / 45 |
prostate | 63% | 322.40 | 154 / 245 | 29% | 0.64 | 147 / 502 |
lymph node | 0% | 0 | 0 / 0 | 90% | 7.11 | 26 / 29 |
adrenal gland | 40% | 205.96 | 104 / 258 | 35% | 0.85 | 80 / 230 |
esophagus | 22% | 119.76 | 321 / 1445 | 52% | 1.94 | 96 / 183 |
peripheral blood | 71% | 560.54 | 660 / 929 | 0% | 0 | 0 / 0 |
skin | 5% | 11.75 | 83 / 1809 | 58% | 2.68 | 274 / 472 |
heart | 59% | 285.42 | 506 / 861 | 0% | 0 | 0 / 0 |
brain | 50% | 177.92 | 1315 / 2642 | 5% | 0.07 | 33 / 705 |
blood vessel | 49% | 252.69 | 651 / 1335 | 0% | 0 | 0 / 0 |
muscle | 29% | 121.36 | 233 / 803 | 0% | 0 | 0 / 0 |
adipose | 15% | 71.31 | 181 / 1204 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 5% | 0.36 | 4 / 80 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0030968 | Biological process | endoplasmic reticulum unfolded protein response |
GO_1904153 | Biological process | negative regulation of retrograde protein transport, ER to cytosol |
GO_0018279 | Biological process | protein N-linked glycosylation via asparagine |
GO_0036503 | Biological process | ERAD pathway |
GO_0005789 | Cellular component | endoplasmic reticulum membrane |
GO_0044877 | Molecular function | protein-containing complex binding |
GO_0005047 | Molecular function | signal recognition particle binding |
GO_0005515 | Molecular function | protein binding |
Gene name | DERL3 |
Protein name | Derlin-3 (Degradation in endoplasmic reticulum protein 3) (DERtrin-3) (Der1-like protein 3) Derlin |
Synonyms | LLN2 DER3 C22orf14 |
Description | FUNCTION: Functional component of endoplasmic reticulum-associated degradation (ERAD) for misfolded lumenal glycoproteins, but not that of misfolded nonglycoproteins. May act by forming a channel that allows the retrotranslocation of misfolded glycoproteins into the cytosol where they are ubiquitinated and degraded by the proteasome. May mediate the interaction between VCP and the misfolded glycoproteins . May be involved in endoplasmic reticulum stress-induced pre-emptive quality control, a mechanism that selectively attenuates the translocation of newly synthesized proteins into the endoplasmic reticulum and reroutes them to the cytosol for proteasomal degradation . . FUNCTION: Functional component of endoplasmic reticulum-associated degradation (ERAD) for misfolded lumenal proteins. May act by forming a channel that allows the retrotranslocation of misfolded proteins into the cytosol where they are ubiquitinated and degraded by the proteasome. . |
Accessions | E7EVA4 ENST00000318109.12 [Q96Q80-1] ENST00000620697.3 [Q96Q80-2] ENST00000628868.1 [Q96Q80-5] ENST00000404056.1 Q96Q80 ENST00000476077.1 [Q96Q80-5] ENST00000614504.3 ENST00000631305.2 [Q96Q80-1] ENST00000406855.7 [Q96Q80-2] |